Article information
Abstract
Hip fractures in the elderly is a health problem of first magnitude, with an incidence which is increasing exponentially. The surgery of these fractures, despite progress in recent years in terms of surgical and anesthetic techniques, the widespread use of thromboprophylaxis and better medical cares, remains a high risk procedure in terms of morbidity and mortality.
Keywords:
Thromboembolic prophylaxis
Hip fracture
Resumen
La fractura de cadera en el anciano constituye un problema sanitario de primera magnitud, con una incidencia en crecimiento exponencial. La cirugía de estas fracturas, a pesar de los avances de los últimos años en cuanto a las técnicas quirúrgicas y anestésicas, a la generalización de la profilaxis tromboembólica y a unos mejores cuidados médicos, continúa siendo un procedimiento de alto riesgo en cuanto a morbilidad y mortalidad
Palabras clave:
Profilaxis tromboembólica
Fractura de cadera
Full text is only aviable in PDF
References
[1.]
N. Rosencher, C. Vielpeau, J. Emmerich, F. Fagnani, M. Samama.
Venous thromboembolism and mortality after hip fracture surgery: The ESCORTE study.
J Thromb Haemost, 3 (2005), pp. 2006-2014
[2.]
H.R. Zahn, J.A. Skinner, M.J. Porteous.
The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation.
Injury, 30 (1999), pp. 605-607
[3.]
J. Granero.
Grupo de Estudio del Tromboembolismo de la SECOT.
Guía de profilaxis tromboembólica en COT, Ed MMC, (2007),
[4.]
W.H. Geerts, D. Berqvist, G.T. Pineo, et al.
Prevention of venous thromboembolism: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines (8th edition).
Chest, 133 (2008), pp. 381-453
[5.]
C.G. Moran, R.T. Wenn, M. Sikand, A.M. Taylor.
Early mortality after hip fracture: is delay before surgery important?.
J Bone Joint Surg (Am), 87 (2005), pp. 483-489
[6.]
B.I. Eriksson, M.R. Lassen, Pentasaccharide in Hip Fracture Surgery Plus Investigators.
Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebocontrolled, double-blind study.
Arch Intern Med, 163 (2003), pp. 1337-1342
[7.]
I. McNamara, A. Sharma, T. Prevost, M. Parker.
Symptomatic venous thromboembolism following a hip fracture. Incidence and risk factors in 5300 patients.
Acta Orthopaedica, 80 (2009), pp. 687-692
[8.]
The TIFDED Study Group.
Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin.
Haemostasis, 29 (1999), pp. 310-317
[9.]
B.I. Eriksson, K.A. Bauer, M.R. Lassen, A.G. Turpie.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
N Engl J Med, 345 (2001), pp. 1298-1304
[10.]
N. Dahlgren, K. Thornebrandt.
Neurological complications after anaesthesia. A follow-up of 18000 spinal or epidural anaesthetics performed over three years.
Acta Anaesthesiol Scan, 39 (1995), pp. 872-880
[11.]
J.V. Llau Pitarch, J. de Andrés Ibánez, C. Gomar Sancho, et al.
Guía clínica de fármacos inhibidores de la hemostasia y anestesia regional neuroaxial.
Rev Esp Anestesiol Reanim, 52 (2005), pp. 413-420
[12.]
D. Wilson, E.A. Cooke, M.A. Mc Nally, H.K. Wilson, A. Yeates, R.A. Mollan.
Changes in coagulability as measured by thromboelastography following surgery for proximal femoral fracture.
Injury, 32 (2001), pp. 765-770
[13.]
K. Hitos, J.P. Fletcher.
Venous thromboembolism and fractured neck of femur.
Thromb Haemost, 94 (2005), pp. 991-996
[14.]
Anand Sanjeev, Buch Keyur.
Post-discharge symptomatic thromboembolic events in hip fracture patients.
Ann R Coll Surg Engl, 89 (2007), pp. 517-520
[15.]
Boehringer Ingelheim. Pradaxa. Monografía de producto basada en la autorización de la UE. Noviembre 2008.
[16.]
Bayer Schering Pharma. Xarelto. Monografía de producto basada en la autorización de la UE. Noviembre 2009.
[17.]
S. Sasaki, N. Miyakoshi, H. Matsuura, H. Saitoh, D. Kudoh, Y. Shimada.
Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery.
J Orthop Sci, 14 (2009), pp. 491-496
[18.]
E.A. Nutescu, S.A. Spinler, A. Wittkowsky, W.E. Dager.
Low-Molecular-Weight heparins in renal impairement and obesity: Available evidence and clinical practice recommendations across medical and surgical settings.
Ann Pharmacother, 43 (2009), pp. 1064-1083
[19.]
W. Burger, J.M. Chemnitius, G.D. Kneissl, G. Rücker.
Low-dose aspirin for secondary cardiovascular prevention. Cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation. Review and meta-analysis.
J Intern Med, 257 (2005), pp. 399-414
Copyright © 2011. Sociedad Española de Cirugía Ortopédica y Traumatología (SECOT). All rights reserved
